Interleukin-22 secreted by NKp44 natural killer cells promotes proliferation of fibroblast-like synoviocytes in rheumatoid arthritis

Medicine (United States)

Volumn 94, Issue 52, 2015, Pages

  Zhu, Junqing ^a   Jia, Ertao ^a   Zhou, Yi ^b   Xu, Juan ^a   Feng, Zhitao ^a   Wang, Hao ^a   Chen, Xiaoguang ^a   Li, Juan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangdong Women and Children Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 22; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; STAT3 PROTEIN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; NCR2 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL EXPANSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KNEE OSTEOARTHRITIS; MALE; NATURAL KILLER CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUPERNATANT; SYNOVIAL FLUID; SYNOVIOCYTE; CELL CULTURE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SYNOVIUM;

ADULT; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKINS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL FLUID; SYNOVIAL MEMBRANE;

EID: 84954498968     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002137     Document Type: Article

References (30)

1. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. The Lancet. 2009;373:659-672.
2. Bombardier C, Barbieri M, Parthan A, et al. The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis. 2012;71:836-844.
3. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1-12.
4. Zhu J, Zhou Y, Chen X, et al. A Metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol. 2014;41:1282-1289.
5. Alivernini S, Fedele AL, Cuoghi I, et al. Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. Reumatismo. 2008;60:85-94.
6. Rodriguez-Fernandez JL. Antigen presentation by dendritic cells in rheumatoid arthritis. Curr Top Med Chem. 2013;13:712-719.
7. Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-2219.
8. Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am. 2001;27:355-371.
9. Ahern DJ, Brennan FM. The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: Major contributors or essential homeostatic modulators? Immunol Lett. 2010.
10. Soderstrom K, Stein E, Colmenero P, et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci USA. 2010;107:13028-13033.
11. Lo CK, Lam QL, Sun L, et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. Arthritis Rheum. 2008;58:2700-2711.
12. Cella M, Fuchs A, Vermi W, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722-725.
13. Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-22 and IL-22-producing NKp44() NK cells in the subclinical gut inflammation of patients with ankylosing spondylitis. Arthritis Rheum. 2011.
14. Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis. 2012;71:295-301.
15. Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 2005;52:1037-1046.
16. Ren J, Feng Z, Lv Z, et al. Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-alpha. J Rheumatol. 2011;38:2112-2118.
17. de Matos CT, Berg L, Michaelsson J, et al. Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology. 2007; 122:291-301.
18. Neidhart M, Seemayer CA, Hummel KM, et al. Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo. Arthritis Rheum. 2003;48:1873-1880.
19. Ota F, Maeshima A, Yamashita S, et al. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2003;48:2442-2449.
20. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32:1650-1653.
21. Luci C, Reynders A, Ivanov II, et al. Influence of the transcription factor RORgammat on the development of NKp46 cell populations in gut and skin. Nat Immunol. 2009;10:75-82.
22. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10:864-871.
23. Pan HF, Li XP, Zheng SG, et al. Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev. 2012.
24. Meroni PL, Valesini G. Tumour necrosis factor alpha antagonists in the treatment of rheumatoid arthritis: an immunological perspective. Bio Drugs. 2014;28(Suppl 1):S5-S13.
25. van Hamburg JP, Corneth OB, Paulissen SM, et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Ann Rheum Dis. 2013;72:1700-1707.
26. Ren J, Zhou Y, Wu H, et al. Role and mechanism of NKp44NK cells in the proliferation and inflammation of synovium of rheumatoid arthritis patients. Zhonghua Yi Xue Za Zhi. 2014;94:201-203.
27. Lejeune D, Dumoutier L, Constantinescu S, et al. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277:33676-33682.
28. Yang X, Zheng SG. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev. 2014;13:615-620.
29. Nielsen N, Pascal V, Fasth AE, et al. Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine NK degranulation towards RA synovial fibroblasts. Immunology. 2014.
30. Kim KW, Kim HR, Park JY, et al. Interleukin-22 promotes osteoclas-togenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2012;64:1015-1023.